Nivolumab (NIVO), a programmed cell death protein 1 (PD-1) inhibitor, has been evaluated as first-line AML therapy in combination with idarubicin and AraC and has yielded encouraging responses in TP53mut patients [96]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.